Mahesh Krishnan, M.D., has served on the Halozyme Board of Directors since 2024 and serves on the Nominating and Corporate Governance Committee and the Compensation Committee. He brings more than 20 years of health care practitioner and biotechnology and health service industry experience.
Since 2009, Dr. Krishnan has served in various roles at DaVita, Inc., a provider of kidney dialysis services, including co-lead of the DaVita Venture Group, its external innovation arm, where he oversees corporate development and mergers and acquisitions. Since May 2019 he has served as DaVita's Group Vice President of Research and Development, and prior to that as DaVita's first international Chief Medical Officer from 2015 to May 2019. From 2004 to 2009 he held various roles at Amgen Inc., including Global Development Leader for Epogen and Executive Director, Medical Policy for all of Amgen's domestic products. From 2000 to 2004 he was a practicing nephrologist at Virginia Nephrology Group.
He earned his M.D. from Jefferson Medical College at Thomas Jefferson University, his B.S. in pre-medicine from The Pennsylvania State University, an M.P.H. from Johns Hopkins University, and an M.B.A. in health care management from the Johns Hopkins Carey School of Business.